Cancer Care Innovations Abound, but Access and Equity Are Ongoing ChallengesByRose McNultyMay 20th 2025
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape EvolvesByLaura Joszt, MAMay 19th 2025
Understanding What Recent Court Action Means to 340B ReformByDinesh Kabaleeswaran,Produced by Mary CaffreyMay 19th 2025
Ajai Chari, MD, on the Challenges of Bringing CAR T, Bispecifics to Patients With Multiple MyelomaByAjai Chari, MD,Kyle MunzMay 18th 2025
Advances in Ovarian Cancer: Using Genomics and Optimizing Maintenance TherapyByAmy VanGalder, PharmD, BCOPMay 18th 2025
Reinventing Oncology: The Urgent Need to Address Access, Burnout, and Adherence in a Shifting LandscapeByPallav Mehta, MDMay 5th 2025
Orca-T Shows Efficacy, Reduced GVHD Risk in Acute Leukemia, MDSByCaspian Oliai, MD, MS,Mary Caffrey,Rose McNultyMay 1st 2025
While Claiming Transparency, CMS Quietly Drops Health Equity Elements of EOMByMary CaffreyApril 22nd 2025
With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance PeriodByMary CaffreyApril 22nd 2025
North Idaho Clinics Become Part of OneOncologyApril 8th 2025The Nashville-based managed services organization now serves 1300 providers and 747,000 patients across 420 sites of care.
As Court Action Heats Up, Study Shows More Money Made on 340B in Wealthy AreasByMary CaffreyApril 3rd 2025The findings appear as multiple lawsuits pit pharmaceutical companies against hospitals as well as HHS.